The MURB 2 study is a phase 2, 12-week randomized, double-blind, placebo-controlled trial that will investigate the use of injectable Buprenorphine (BUP) compared to injectable placebo (PBO-Inj) for the treatment of methamphetamine use disorder among individuals with mild co-use of opioid misuse. Twice weekly appointments will be made during 12 weeks of the medication phase.
What is the purpose of this study?
The purpose of this study is to evaluate whether injectable Buprenorphine compare to injectable placebo reduces methamphetamine use in participants with moderate to severe methamphetamine use disorder with co-occuring mild opioid use disorder or opioid misuse. Twice weekly appointments will be made during the 12 weeks of the medication phase.
You may qualify if you are:
- 18 - 65 years of age
- Interested in reducing or stopping methamphetamine use
- Be willing to comply with all study procedures and medication instructions